Security Snapshot

RECURSION PHARMACEUTICALS IN - CL A Institutional Ownership

CUSIP: 75629V104

13F Institutional Holders and Ownership History from Q4 2023 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

0

Shares (Excl. Options)

0

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Type / Class
Equity / CL A
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
0
Total reported value
$0
Share change
-7,706,363
Value change
-$37,607,051
Number of holders
0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • 75629V104 - RECURSION PHARMACEUTICALS IN - CL A is tracked under CUSIP 75629V104.
  • 0 institutions reported positions in Q4 2025.
  • Schedule 13D/13G significant owner rows are not currently available.

What Changed

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • Reported value moved from $37,607,051 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 0 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 75629V104?
CUSIP 75629V104 identifies 75629V104 - RECURSION PHARMACEUTICALS IN - CL A in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of RECURSION PHARMACEUTICALS IN - CL A.

Institutional Holders of RECURSION PHARMACEUTICALS IN - CL A across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$37,607,051 0
2025 Q3 7,706,363 $37,607,051 $4.88 1
2024 Q3 12,870,272 $84,815,092 +$27,155,314 $6.59 1
2024 Q2 26,059,749 $195,448,120 +$25,397,685 $7.50 2
2024 Q1 22,673,391 $226,053,710 -$18,665,106 $9.97 2
2023 Q4 24,545,518 $242,018,806 $9.86 2
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .